共 50 条
DECITABINE FOR ACUTE MYELOID LEUKEMIA IN A PATIENT UNDERGOING HEMODIALYSIS
被引:4
|作者:
Kourelis, T. V.
[1
]
Moustakakis, M. N.
[2
]
Silk, R.
Pharm, D.
[3
]
Boruchov, A.
[2
]
Bilgrami, S. F.
[2
]
机构:
[1] Univ Connecticut, Sch Med, Dept Med, Farmington, CT 06103 USA
[2] St Francis Hosp & Med Ctr, Dept Med, Hartford, CT 06105 USA
[3] St Francis Hosp & Med Ctr, Dept Pharm, Hartford, CT USA
关键词:
acute myeloid leukemia;
decitabine;
hemodialysis;
MYELODYSPLASTIC SYNDROME;
PHARMACOKINETICS;
5-AZA-2-DEOXYCYTIDINE;
PHARMACOLOGY;
THERAPY;
D O I:
10.1177/1721727X1100900310
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Treatment of patients with Acute Myeloid Leukemia (AML) undergoing hemodialysis is especially challenging since there are no specific management guidelines for the administration of cytotoxic agents in these patients. Well established chemotherapy protocols may be unsuitable in such cases because of altered drug pharmacokinetics, increased risk for complications, and underlying co-morbidities. In addition, these patients are at an increased risk for complications such as tumor lysis syndrome. Herein, we report the first use of decitabine in a patient on hemodialysis. He presented with a new diagnosis of AML and achieved hematologic remission following the use of induction chemotherapy and maintenance decitabine.
引用
收藏
页码:289 / 292
页数:4
相关论文